Stockscreener 앱 받기
0.95
0.02%
-0.0002
시간 외 거래:
.95
Matinas Biopharma Holdings Inc 주식(MTNB)의 최신 뉴스
Is Matinas BioPharma Holdings Inc. a good long term investmentBreakthrough profit margins - Autocar Professional
What analysts say about HASI stockFree Investment Timing Strategies - jammulinksnews.com
How Matinas BioPharma Holdings Inc. stock performs during market volatilitySmart Return Focused Trading - Newser
Matinas BioPharma Holdings Inc. Stock Analysis and ForecastBreakout profit opportunities - jammulinksnews.com
What drives Matinas BioPharma Holdings Inc. stock priceFree Stock Market Mentorship - jammulinksnews.com
What analysts say about Matinas BioPharma Holdings Inc. stockExceptional portfolio growth - Autocar Professional
Is Renovaro Inc. a good long term investmentSuperior capital gains - jammulinksnews.com
What makes Matinas BioPharma Holdings Inc. stock price move sharplyShort Squeeze Radar - beatles.ru
What analysts say about WRAP stockOutstanding capital returns - jammulinksnews.com
Why Matinas BioPharma Holdings Inc. stock attracts strong analyst attentionQuick Profit Idea Stream - Newser
Why Hayward Holdings Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
Aspergillosis Pipeline 2025: FDA Updates, Therapy - openPR.com
Diversification Wins: Global ETFs Shine in First Half of 2025 - The Globe and Mail
MTNB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Pre-market Movers: HCTI, KLTO, INTS, HSDT... - RTTNews
Kalkine Matinas BioPharma Surges Amid NYSE Composite Market Momentum - Kalkine Media
Matinas Biopharma (NYSE:MTNB) Trading 5.7% Higher – Here’s Why - Defense World
Matinas Biopharma (NYSE:MTNB) versus Marker Therapeutics (NASDAQ:MRKR) Head to Head Review - Defense World
Matinas BioPharma amends bylaws, updates on officer agreements By Investing.com - Investing.com Canada
Matinas BioPharma Amends Bylaws and Sets Annual Meeting - TipRanks
Matinas BioPharma amends bylaws, updates on officer agreements - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Matinas Biopharma (NYSE:MTNB) Shares Down 2.6% – Here’s What Happened - Defense World
MTNB stock touches 52-week low at $0.48 amid sharp annual decline - Investing.com Australia
MTNB stock touches 52-week low at $0.48 amid sharp annual decline By Investing.com - Investing.com South Africa
Matinas BioPharma secures shareholder nods on key proposals By Investing.com - Investing.com Australia
4.91%
0.25%
자본화:
|
볼륨(24시간):